ReviewMolecular cancer2018

Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.

Wagner Ricardo Montor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.